canada clinical guidance

Psychosis & schizophrenia: early recognition + physical health monitoring

A Canadian clinical summary of psychosis & schizophrenia: early recognition + physical health monitoring, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian Schizophrenia Guidelines. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CPA schizophrenia

Source-attributed clinical priorities

  • Arrange early coordinated assessment for first-episode psychosis and address immediate risk, substance use and medical mimics.
  • Pair antipsychotic treatment with psychosocial, family, vocational and physical-health care.
  • Monitor cardiometabolic and movement adverse effects and assess adherence before labelling treatment resistance.
  • Reduce the duration of untreated psychosis by connecting a first episode directly to an early-intervention service.
sources for this section:CPA schizophrenia

Practical assessment and management workflow

1
Assess hallucinations, delusions, disorganization, negative symptoms, cognition, mood, substances and functional decline.
2
Perform physical and neurologic examination and targeted investigations for intoxication, withdrawal or medical mimics.
3
Agree on antipsychotic choice with attention to prior response, metabolic risk, movement effects and formulation preference.
4
Review response, adherence, family needs, housing, education or work and physical health through coordinated follow-up.
sources for this section:CPA schizophrenia

Safety, red flags and urgent escalation

  • Escalate command hallucinations with intent, severe agitation, catatonia, inability to eat or drink, or acute medical toxicity.
  • Monitor weight, waist, blood pressure, glucose, lipids and movement symptoms from treatment initiation.
  • Suspected neuroleptic malignant syndrome requires immediate drug cessation and emergency care.
sources for this section:CPA schizophrenia

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CPA schizophrenia

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CPA schizophrenia

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Psychiatric AssociationCanadian Schizophrenia Guidelinesaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.